Agios製藥 AGIO 深 滬
等待開盤 11-26 09:30:00 美东时间
28.425
+1.935
+7.30%
華盛通- 最 高28.63
- 今 開27.19
- 成交量 229.81万股
- 最 低 26.36
- 昨 收 26.49
- 總市值 16.58亿
- 52周最高 57.33
- 市盈率 靜 2.44
- 換手率 3.94%
- 52周最低 22.24
- 委 比 -99.94%
- 總股本 5831.38万
- 歷史最高 138.85
- 量 比 0.34
- 振 幅 8.57%
- 歷史最低 15.77
- 每 手 1
- 風險率 6.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
美股周涨跌榜 | 社交电商平台WeShop上市一周涨超275%；精密科学周涨超50%，获雅培230亿美元收购
社交电商平台WeShop上市一周涨超275%；精密科学周涨超50%，获雅培230亿美元收购；SEMrush周涨近67%，获Adobe收购>>
11-22 10:30
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $48
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $56 to $48.
11-20 18:08
Why Is Agios Pharmaceuticals Stock Sinking Today?
Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises, prompting mixed investor reaction.
11-20 01:30
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Kazia Therapeutics (NASDAQ:KZIA) shares increased by 51.6% to $8.73 du...
11-19 20:05
Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
Agios Pharmaceuticals Q3 EPS $(1.78) Beats $(1.91) Estimate, Sales $12.880M Beat $10.417M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of $(1.91) by 7 percent. This is a 110.97 percent decrease over earnings of $16.22 per share
10-30 18:35
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals reported Q3 2025 financial results and updates, highlighting $12.9 million net revenue for PYRUKYND® (mitapivat), an increase of 44% YoY. The FDA extended the PDUFA goal date for PYRUKYND's sNDA in thalassemia to December 7, 2025, due to a request for a REMS program. The CHMP adopted a positive opinion for PYRUKYND in thalassemia, with an EC decision expected by early 2026. Topline RISE UP Phase 3 trial results in sickle cel...
10-30 10:30
